Alnylam Pharmaceuticals of the USA has linked up with Germany's
Ribopharma to create what it claims is a world leading company in
the development of RNAi-based therapeutics. First drug may be in
trials this year.
Roche has licensed exclusive marketing rights outside the USA to
Avastin (bevacizumab), a drug for colorectal cancer, from
Genentech. The latter company will retain all rights to the drug in
its home market.
A UK Phase I trial has been initiated for XR5944 (also known as
MLN944), a DNA targeting agent under evaluation for the treatment
of advanced cancers. The product is under development by USA-based
firm Millennium Pharmaceuticals and...
The European Commission has issued its long-awaited response to the
G10 Medicines Report, intended as a blueprint for improving the
European pharmaceutical industry's competitiveness while ensuring
high levels of public health...
Switzerland's Tecan has introduced a range of laboratory automation
workstations, under the Freedom EVO banner, which are designed to
provide fluid handling applications in genomics, proteomics, drug
discovery and clinical diagnostics.